BioNTech SE, a pioneer in mRNA therapeutics, reported a substantial net loss in FY2025 following a decline in COVID-19 vaccine revenues and increased operating expenses related to pipeline prioritization and legal settlements. Despite these setbacks, the company continues to invest heavily in immuno-oncology, antibody-drug conjugates, and strategic collaborations, notably with Bristol-Myers Squibb. Its robust liquidity and patent moat underpin growth prospects, but future profitability hinges on successful late-stage clinical outcomes and effective cost management.